Skip to main content

Table 1 Baseline characteristics and biochemical assessments in type 2 diabetic patients

From: Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus

Variables CAD (+) CAD (−) P value
(n = 144) (n = 61)
Male, n (%) 108 (75.0) 37 (60.7) 0.039
Age, years 64.8 ± 10.3 65.3 ± 9.1 0.728
Body mass index, Kg/m2 25.5 ± 3.4 24.9 ± 3.1 0.262
Smoking, n (%) 50 (34.7) 11 (18.0) 0.017
Hypertension (%) 110 (76.4) 37 (60.7) 0.022
Systolic blood pressure, mmHg 140 ± 19 139 ± 20 0.572
Diastolic blood pressure,mmHg 81 ± 12 81 ± 11 0.603
Dyslipidemia history, n (%) 57 (39.6) 23 (37.7) 0.801
Triglycerides, mmol/L 1.82 ± 1.09 1.75 ± 0.96 0.671
Total cholesterol, mmol/L 4.3 ± 1.2 4.4 ± 1.0 0.753
HDL cholesterol, mmol/L 1.01 ± 0.24 1.13 ± 0.22 0.001
LDL cholesterol, mmol/L 2.63 ± 0.93 2.56 ± 0.76 0.616
Lipoprotein (a), g/L 0.27 ± 0.25 0.28 ± 0.26 0.666
Apoprotein A, g/L 1.20 ± 0.19 1.23 ± 0.20 0.310
Apoprotein B, g/L 0.91 ± 0.26 0.88 ± 0.20 0.460
Serum creatinine, μmol/L 81 ± 17 75 ± 14 0.011
eGFR, mL/min/1.73 m2 92.3 ± 24.4 96.8 ± 23.6 0.228
Uric acid, μmol/L 342 ± 89 325 ± 83 0.199
Fasting blood glucose, mmol/L 6.79 ± 2.00 6.02 ± 1.33 0.001
HbA1c, % 7.81 ± 1.07 6.89 ± 0.75 <0.001
hsCRP, mg/L 6.20 ± 3.24 5.21 ± 2.42 0.040
Extent index 0.48 ± 0.13 0.27 ± 0.08 <0.001
Cumulative coronary stenosis score 2.17 ± 0.71 0.92 ± 0.42 <0.001
Relative intensity of apoA-I glycation, % 8.27 ± 2.09 5.69 ± 1.42 <0.001
Activities of paraoxonase, U/mL
 Serum PON1 activity 78.46 ± 16.94 86.01 ± 17.36 0.004
 HDL-associated PON1 activity 41.43 ± 14.64 92.19 ± 33.42 <0.001
 Serum PON3 activity 32.15 ± 5.33 39.2 ± 6.62 <0.001
 HDL-associated PON3 activity 26.06 ± 12.66 64.58 ± 22.44 <0.001
Medical treatments, n (%)
 Insulins 51 (35.4) 11 (18.0) 0.013
 Metformin 70 (48.6) 31 (50.8) 0.772
 Sulphonylurea 41 (28.5) 25 (41.0) 0.080
 α-Glucosidase 40 (27.8) 18 (29.5) 0.801
 Statin 107 (74.3) 43 (70.5) 0.573
 ACE inhibitor/ARB 88 (61.1) 37 (60.7) 0.951
 β-blocker 82 (56.9) 34 (55.7) 0.873
 Calcium channel blocker 73 (50.7) 39 (63.9) 0.082
 Antiplatelet 107 (74.3) 36 (59.0) 0.029
  1. Data are mean ± SD and number (%)
  2. ACE, angiotensin-converting enzyme; apoA-I, apolipoprotein A-I; ARB, angiotensin receptor blocker; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobinA1c; HDL, high-density lipoprotein; hsCRP, high-sentivity C-reactive protein; LDL, low densitylipoprotein, PON, paraoxonase
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840